IL36A and Alzheimer disease: Of note, the significant difference in IL-36α expression between lesional and nonlesional skin observed in our study suggests the possibility of IL-36α as a potential biomarker to discriminate lesional from nonlesional skin and may be helpful in the monitoring of the improvement of skin lesions in AD patients.